|Bid||52.31 x 1100|
|Ask||52.32 x 800|
|Day's Range||52.23 - 52.81|
|52 Week Range||41.23 - 52.84|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||21.24|
|Forward Dividend & Yield||1.25 (2.37%)|
|1y Target Est||N/A|
BOSTON, Aug. 14, 2019 /PRNewswire/ -- Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where companies develop truly transformational science. Novo Nordisk, a global healthcare company committed to discovering, creating and co-creating innovation to solve healthcare challenges for people living with diabetes and other serious chronic diseases, issues an open call for promising start-up companies to submit non-confidential proposals for a Novo Nordisk-sponsored LabCentral "Golden Ticket." The winner will have the chance to receive access for one scientist and one bench at LabCentral's state-of-the-art shared lab space in Boston for research for one year.
PLAINSBORO, N.J., April 30, 2019 /PRNewswire/ -- Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero carbon emissions from operations and transportation. The announcement follows a $70 million investment in a 105-megawatt dc solar energy installation to be built in Pender County, North Carolina. When completed, ground-mounted solar arrays will harvest sunlight and provide renewable electricity to all existing Novo Nordisk US offices, laboratories and manufacturing facilities as well as to support the new manufacturing facility under construction in Clayton, N.C. Developed and constructed by Cypress Creek Renewables, the solar panel installation will be one of North Carolina's largest solar sites.
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
Government of Quebec provides adults living with diabetes mellitus access to ultra-long-acting insulin, TRESIBA®
Ontario becomes first province to provide public funding of TRESIBA® for adults with diabetes mellitus